Clinical pharmacology of HIV protease inhibitors in pregnancy

Current Opinion in HIV and AIDS

Volumn 3, Issue 6, 2008, Pages 620-626

  Van Der Lugt, Jasper ^a,b   Colbers, Angela ^c   Burger, David ^c  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b International Antiretroviral Trial Evaluation Centre   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Mother to child transmission; Pharmacokinetics; Pregnancy; Protease inhibitor

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CYTOCHROME P450 3A4; INDINAVIR; INDINAVIR PLUS RITONAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MESYLIC ACID ETHYL ESTER; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; VIRUS RNA;

AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL PHARMACOLOGY; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG CONTAMINATION; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG SAFETY; ENZYME ACTIVITY; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INSULIN RESISTANCE; LACTATE BLOOD LEVEL; LIPID BLOOD LEVEL; LOW BIRTH WEIGHT; NONHUMAN; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TABLET FORMULATION; THIRD TRIMESTER PREGNANCY; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VIRUS INHIBITION; VIRUS LOAD;

EID: 67649628165     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283136cc5     Document Type: Review

References (41)

1. UNAIDS, WHO. AIDS epidemic update: December 2007. Geneva: UNAIDS; 2007.
2. Squires KE. HIV infection in women: management across the continuum [presentation]. American Conference for the Treatment of HIV (ACTHIV); 31 May-03 June 2007; Dallas: ACTHIV; 2007.
3. Harris NS, Fowler MG, Sansom SL, et al. Use of enhanced perinatal human immunodeficiency virus surveillance methods to assess antiretroviral use and perinatal human immunodeficiency virus transmission in the United States, 1999-2001. Am J Obstet Gynecol 2007; 197 (3 Suppl):S33-S41.
4. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296:827-843.
5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. pp. 1-128. http://www aidsinfo nih gov/ContentFiles/AdultandAdolescentGL pdf. [Accessed 29 January 2008 and 30 June 2008].
6. Roustit M, Jlaiel M, Leclercq P, Stanke-Labesque F. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br J Clin Pharmacol 2008 [Epub ahead of print]. Most recent and complete review on pharmacokinetics of ARV during pregnancy.
7. Aweeka F, Stek A, Best B, et al. Lopinavir protein binding during pregnancy [abstract #787]. In: 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles: CROI; 2007. This study shows an increased unbound fraction of lopinavir as a result of the pregnancy.
8. Zhang H, Wu X, Wang H, et al. Effect of pregnancy on cytochrome P450 3a and P-glycoprotein expression and activity in the mouse: mechanisms, tissue specificity, and time course. Mol Pharmacol 2008 [Epub ahead of print]. This study gives a good insight about the role of CYP450 activity during pregnancy.
9. Ripamonti D, Cattaneo D, Maggiolo F, et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 2007; 21:2409-2415. The first paper with 24 h pharmacokinetic that compares antepartum and postpartum curves.
10. Eley T, Vandeloise E, Chil M, et al. Steady state pharmacokinetics and safety of atazanavir after treatment with ATV 300mg once daily/ritonavir 100 mg once daily+ZDV/3TC during the third trimester in HIV+ women [abstract #624]. In: 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, Massachusetts: CROI; 2008. A recent study that compares antepartum and postpartum curves of atazanavir.
11. Natha M, Hay P, Taylor G, et al. Atazanavir use in pregnancy: a report of 33 cases [abstract #750]. In: 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles: CROI; 2007.
12. Ferreira C, Floch-Tudal C, Meier F, et al. Atazanavir in pregnancy: influence on neonatal hyperbilirubinemia [abstract #625]. In: 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston: CROI; 2008.
13. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20:1931-1939.
14. Lyons F, Lechelt M, De RA. Steady-state lopinavir levels in third trimester of pregnancy. AIDS 2007; 21:1053-1054.
15. Manavi K, McDonald A, Al-Sharqui A. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine. AIDS 2007; 21:643-645. This study describes trough levels of several ARVs during pregnancy.
16. Peyvatin G, Pierr-François S, Cassard B, et al. Reduced lopinavir exposure during pregnancy: a case control study [abstract #579]. In: 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles: CROI; 2007.
17. Khuong-Josses M, Boussaïri A, Palette C, Mé chali D. Lopinavir drug monitoring in 36 pregnant women [abstract #743]. In: 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles: CROI; 2007.
18. van der Lugt J, Molto J, Hawkins D, et al. The influence of pregnancy on the pharmacokinetics of saquinavir boosted by low-dose ritonavir (1000/100 mg BID) [abstract]. In: 9th International Workshop on Clinical Pharmacology of HIV Therapy; 7-9 April 2008; New Orleans; 2008. This study extensively describes pharmacokinetic curves of saquinavir in the second and third trimester and postpartum.
19. Lopez-Cortes LF, Ruiz-Valderas R, Rivero A, et al. Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy. Ther Drug Monit 2007; 29:171-176.
20. Unadkat JD, Wara DW, Hughes MD, et al. Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2007; 51:783-786. Most recent study that describes antepartum and postpartum pharmacokinetic curves of indinavir.
21. min concentrations.
22. Villani P, Floridia M, Pirillo MF, et al. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol 2006; 62:309-315.
23. Read J, Best B, Stek A, et al. Nelfinavir pharmacokinetics (625-mg tablets) during the third trimester of pregnancy and postpartum [abstract #740]. In: 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles: CROI; 2007. A recent study that compares antepartum and postpartum pharmacokinetic curves of nelfinavir.
24. Klein CE, Chiu YL, Awni W, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 2007; 44:401-410.
25. Hirt D, Urien S, Jullien V, et al. Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples. Br J Clin Pharmacol 2007; 64:634-644.
26. Volmink J, Siegfried NL, van der ML, Brocklehurst P. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2007:CD003510.
27. Centers for Disease Control and Prevention (CDC). Achievements in public health. Reduction in perinatal transmission of HIV infection: United States, 1985-2005. MMWR Morb Mortal Wkly Rep 2006; 55:592-597.
28. Zorrilla CD, Van DR, Bardeguez A, et al. Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants. Antimicrob Agents Chemother 2007; 51:2208-2210.
29. Kakehasi FM, Tupinambas U, Cleto S, et al. Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy. AIDS Res Hum Retroviruses 2007; 23:1515-1520.
30. Patel D, Cortina-Borja M, Thorne C, Newell ML. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis 2007; 44:1647-1656. One of the few large studies that looks into efficacy of different ARV regimens during pregnancy
31. Jao E, Calvet G, Sidi L, et al. Virologic control and infant outcomes among pregnant women exposed to different ART regimens during pregnancy [abstract #757]. In: 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles: CROI; 2007.
32. Perinatal HIV Guidelines Working Group. Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. pp. 1-96. http://aidsinfo nih gov/contentfiles/PerinatalGL pdf. [Accessed 2 November 2007 and 30 June 2008].
33. Cunha AM, Hagemann CC, Simoes RS, et al. Effects of lopinavir-ritonavir combined therapy during the rat pregnancy. Morphological and biochemical aspects. Eur J Obstet Gynecol Reprod Biol 2007; 133:60-63.
34. Livingston EG, Cohn SE, Yang Y, et al. Lipids and lactate in human immunodeficiency virus-1 infected pregnancies with or without protease inhibitor-based therapy. Obstet Gynecol 2007; 110 (2 Pt 1):391-397.
35. Hitti J, Andersen J, McComsey G, et al. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol 2007; 196:331-337. This trial evaluates the effect of protease inhibitors on glucose metabolism, and showing no additional risk for developing glucose intolerance when using protease inhibitors in pregnancy.
36. Melvin AJ, Kang M, Hitti J, et al. Cord blood lipids in infants born to HIV-1-infected women treated with combination antiretroviral therapy. Antivir Ther 2008; 13:349-355.
37. Ravizza M,Martinelli P, Bucceri A, et al. Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women. J Infect Dis 2007; 195:913-914.
38. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007; 21:1019-1026. This study indicates that ARV and protease inhibitors in particular, are a risk factor for preterm delivery.
39. Beckerman KP. Protease inhibitor treatment of HIV-1-infected women may protect against extreme prematurity and very low birth weight. J Infect Dis 2007; 196:1270-1271.
40. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 2007; 21:607-615. Despite the suggestion made in other studies about preterm delivery and antiretroviral use, this meta-analysis showed no additional risks for using ARV and protease inhibitors in particular.
41. Mussi-Pinhata MM, Rego MA, Freimanis L, et al. Maternal antiretrovirals and hepatic enzyme, hematologic abnormalities among human immunodeficiency virus type 1-uninfected infants: the NISDI perinatal study. Pediatr Infect Dis J 2007; 26:1032-1037.